To see a world in a grain of sand: Elucidating the pathophysiology of Anderson-Fabry disease through investigations of a cellular model

Kidney International

Volumn 75, Issue 4, 2009, Pages 351-353

  Pastores, Gregory M ^a   Hughes, Derralynn A ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; ALPHA GALACTOSIDASE; GLOBOTRIAOSYLCERAMIDE;

ANTIGEN EXPRESSION; CLINICAL FEATURE; ENZYME REPLACEMENT; EPITHELIUM CELL; FABRY DISEASE; GENE SILENCING; HUMAN; KIDNEY TUBULE CELL; MOLECULAR MODEL; NONHUMAN; NOTE; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL;

EID: 59149096175     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.606     Document Type: Note

References (20)

1. Hebert CG, Valdes JJ, Bentley WE. Beyond silencing - engineering applications of RNA interference and antisense technology for altering cellular phenotype. Curr Opin Biotechnol 2008; 19:500-505.
2. Thomaidis T, Relle M, Golbas M et al. Downregulation of α-galactosidase A upregulates CD77:functional impact for Fabry nephropathy. Kidney Int 2009; 75:399-407.
3. Clarke JT. Narrative review: Fabry disease. Ann Intern Med 2007; 146:425-433.
4. Hopkin RJ, Bissler J, Banikazemi M et al. Characterization of Fabry disease in 352 pediatric patients in the Fabry registry . Pediatr Res 2008; 64:550-555.
5. Hozumi I, Nishizawa M, Ariga T et al. Biochemical and clinical analysis of accumulated glycolipids in symptomatic heterozygotes of angiokeratoma corporis diffusum (Fabry's disease) in comparison with hemizygotes. J Lipid Res 1990; 31:335-340.
6. Vedder AC, Linthorst GE, van Breemen MJ et al. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 2007; 30:68-78.
7. Gupta S, Ries M, Kotsopoulos S et al. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women. Medicine (Baltimore) 2005; 84:261-268.
8. Aerts JM, Groener JE, Kuiper S et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA 2008; 105:2812-2817.
9. Ohshima T, Murray GJ, Swaim WD et al. Alpha-galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci USA 1997; 94:2540-2544.
10. Ohshima T, Schiffmann R, Murray GJ et al. Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice. Proc Natl Acad Sci USA 1999; 96:6423-6427.
11. Eitzman DT, Bodary PF, Shen Y et al. Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis. J Am Soc Nephrol 2003; 14:298-302.
12. S hen Y, Bodary PF, Vargas FB et al. Alpha-galactosidase A deficiency leads to increased tissue fibrin deposition and thrombosis in mice homozygous for the factor V Leiden mutation. Stroke 2006; 37:1106-1108.
13. Bodary PF, Shen Y, Vargas FB et al. Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency. Circulation 2005; 111:629-632.
14. Park JL, Whitesall SE, D'Alecy LG et al. Vascular dysfunction in the α-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect. Clin Exp Pharmacol Physiol 2008; 35:1156-1163.
15. Shu L, Shayman JA. Caveolin-associated accumulation of globotriaosylceramide in the vascular endothelium of alpha-galactosidase A null mice. J Biol Chem 2007; 282:20960-20967.
16. Porubsky S, Luckow B, Bonrouhi M et al. [Glycosphingolipids Gb3 and iGb3: in vivo roles in hemolytic-uremic syndrome and iNKT cell function] (article in German). Pathologe advance online publication, 31 August 2008, doi:10.1007/s00292-008-1040-0.
17. Hein LK, Duplock S, Hopwood JJ et al. Lipid composition of microdomains is altered in a cell model of Gaucher disease. J Lipid Res 2008; 49:1725-1734.
18. Alroy J, Sabnis S, Kopp JB. Renal pathology in Fabry disease. J Am Soc Nephrol 2002; 13(Suppl 2):S134-S138.
19. Nudelman E, Kannagi R, Hakomori S et al. A glycolipid antigen associated with Burkitt lymphoma defined by a monoclonal antibody. Science 1983; 220:509-511.
20. Mangeney M, Lingwood CA, Taga S et al. Apoptosis induced in Burkitt's lymphoma cells via Gb3/CD77, a glycolipid antigen. Cancer Res 1993; 53:5314-5319.